LRP1 and Alzheimer disease: Granule calcium protein (GCA) competes with Aβ for LRP1 binding in microglia and treatment with GCA-neutralizing antibodies has been shown to increase LRP1 levels and inhibit AD progression (Zhou et al., 2023).